Dr. Reddy's: Stellar Performance - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Dr. Reddy's: Stellar Performance

Nov 1, 2001

Dr. Reddy has recorded an exciting 104% growth in sales and a 420% growth in profit before tax for 2QFY02. Operating margins have leapfrogged to 49.4% in the concerned quarter from 25.9% last year. The performance of the company is much above market expectations. The figures for the current quarter is on a consolidated basis with Cheminor drugs and American Remedies. To provide meaningful comparison, previous quarter numbers are also on a consolidated basis. The surge in revenues and profits was mainly fuelled by generic fluoxetine and other export formulations.

(Rs m)2QFY012QFY02% change1HFY011HFY02% Change
Sales 2,429 4,943 103.5% 4,575 7,782 70.1%
Other Income82 204 149.5%15329089.9%
Expenditure 1,799 2,501 39.0% 3,535 468632.5%
Operating Profit (EBDIT) 630 2,442 287.7% 1,040 3,096 197.8%
Operating Profit Margin (%)25.9%49.4%22.7%39.8%
Interest 11814-87.9%23264-72.3%
Profit before Tax 483 2,510 420.1% 764 3,087 304.0%
Extraordinary Exp/(Income) - 1,083 - 1,083
Tax Provision/(Deferred benefit) net 55-8-114.5%8734-61.1%
Profit after Tax/(Loss) 427 1,435 235.9% 677 1,970 191.1%
Net profit margin (%)17.6%29.0% 14.8%25.3%
No. of Shares (eoy) (m)
Fully Diluted Earnings per share*23.177.618.353.2
P/E (at current price) 21.8 31.7
(**- annualised)

The current quarter witnessed a marked shift in the business mix of the company. Generics business which started with modest sales in 1QFY02 contributed more than 39% of the total turnover. This was mainly fuelled by fluoxetine 40 mg capsules contributing around 35% to the total turnover of the company i.e Rs 1,639 m (US$ 35 m). It may be recalled that Dr. Reddy's received a para IV certifications (which entitles the company to have 180 days generic marketing exclusivity) for fluoxetine in last quarter. The current quarter seems to reflect 60 days (of the 180 days exclusivity) of generic fluoxetine sales. The 180-day marketing exclusivity for Fluoxetine runs between August 2001 and February 2002. The conversion rate for fluoxetine i.e. switch from branded Prozac has been on a steep rise in the last two months and currently stands at around 80%. i.e. 80% of total prescribed sales of the drug in the US is marketed by Dr. Reddy's. The company has recently also received final approval for marketing famotidine and Enalapril tablets in the US. Dr. Reddy's now has a total of 14 ANDA filings including 5 Para IV certifications.

The company also received Rs 236 m (US$ 5 m) from Novartis as upfront payment for the licensing of its diabetic molecule which has been included in the sales revenues.Excluding one time receipt for upfront payment and sales of fluoxetine, revenues have jumped 26%. Domestic formulations sales grew by 7% more or less in line with domestic pharma market growth.

Dr. Reddy's is currently trading at Rs 1,115 on 1HFY02 annualised earnings multiple of 21x. It may be noted however, that the sales of fluoxetine for last two months should not be taken as indicative of next four months exclusivity sales. The sales of the drug are through the company's marketing tie-up with Par Laboratories. It may be the case that Par Laboratories may have stocked up the drug in anticipation of sales. We would be revising our earnings estimates shortly inview of milestone payment receipt and bigger breakthrough in the generics market.

The company has also declared a special interim dividend of 100% I.e. Rs 5 per share.

Equitymaster requests your view! Post a comment on "Dr. Reddy's: Stellar Performance". Click here!


More Views on News

Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

May 24, 2021

With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 3, 2021 (Close)


  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks